UK medical regulator sketches AI-device oversight and closer FDA ties

The UK's Medicines and Healthcare products Regulatory Agency has outlined plans for more adaptable oversight of AI-enabled medical devices as it prepares to address the AdvaMed conference in the United States on October 20. The announcement, issued October 19, describes a shift toward oversight across a device's lifecycle, regulatory sandboxes and closer collaboration with international counterparts.

The approach builds on the agency's MHRA 2030 Strategy, which proposes a dedicated Centre for AI and Digital Health and changes to how AI-based medical products are assessed and monitored. The regulator says its existing AI Airlock sandbox is being used to test how oversight could work for evolving AI devices. Regional work with NHS partners in London and Manchester is intended to generate evidence from real healthcare settings to inform future rules.

The MHRA also says it is recruiting a senior US partnerships official, based in Washington, to act as a liaison to the US Food and Drug Administration under the MHRA-FDA Pioneer Programme. The two regulators intend to increase scientific exchange and coordination, but the announcement explicitly says they will retain independent decision-making authority.

For developers, the prospective changes could influence what evidence is needed as AI-enabled devices are updated after deployment. These are regulatory plans and ongoing pilots, not an announcement that new binding AI-device rules have already taken effect.